Zytoprotec has announced the completion of a Phase I/II clinical trial with its lead product, PD-protec™.

The product is developed to improve the treatment of patients with kidney failure.

“This randomized cross-over trial has shown that PD-protec™ is safe and well-tolerated”, said Dr. Christoph Aufricht, Chief Scientific Officer of Zytoprotec.

Dr. Aufricht continued, “The trial was also designed to provide biological material to be analyzed for indicators of efficacy. While we are currently processing the samples, we see first hints that PD-protec™ may improve survival of abdominal cells in peritoneal dialysis.”

“I am very pleased that Zytoprotec has reached this important clinical milestone for its lead product”, said Peter C. Weilguni, Chief Executive Officer of the Company.

Weilguni continued, “Our development team has demonstrated great discipline and I am confident that we will be able to initiate the Phase II trial with PD-protec™ in autumn this year. We are currently preparing for the financing of this trial, and are in advanced negotiations with a venture fund closely linked to a global pharmaceutical company.”

Karl Altenhuber, co-founder of Zytoprotec and Chairman of its Advisory Board, commented: “I am proud that Zytoprotec advanced from start-up to clinical stage in just five years and built a strong IP-position for its cytoprotective dialysates. It is particularly encouraging to see the substantial interest in the Company and its promising drug programs shown by global pharmaceutical leaders.”